Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making
Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. JCO Oncology Practice 2017, 13: jop.2017.022731. PMID: 29048991, DOI: 10.1200/jop.2017.022731.Peer-Reviewed Original ResearchConceptsAdjuvant therapy decisionsRecurrence scoreChemotherapy useRS testingMedical oncologistsHistorical controlsChemotherapy decisionsTherapy decisionsEligibility criteriaNational Comprehensive Cancer Network guidelinesProspective quality improvement projectEarly-stage breast cancerAdjuvant chemotherapy recommendationsTime of diagnosisTime of surgeryQuality improvement projectTesting groupChemotherapy initiationChemotherapy recommendationsMedian timeTrial enrollmentNetwork guidelinesSurgical oncologistsClinical trialsBreast cancerDevelopment of a complex patient identification process for the CMS’ Oncology Care Model.
Sinanis N, Abdelghany O, Strait M, Lyons C, Adelson K. Development of a complex patient identification process for the CMS’ Oncology Care Model. Journal Of Clinical Oncology 2017, 35: 32-32. DOI: 10.1200/jco.2017.35.8_suppl.32.Peer-Reviewed Original ResearchOncology Care ModelD statusCare modelOral drugsPatient identification processesLast visit dateMedicare Part DEligible patientsEnhanced paymentsOral prescriptionDrug fillsVisit dateSpecialty pharmacyEligibility criteriaPatientsCare managementMedicare Part BPatient identificationNew prescriptionsMedicare Part B.DrugsPrescriptionPart DStepwise approachInsurance information